3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
69
Fallopian Tube Neoplasms
18
Endometrial Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Breast Neoplasms
7
Neoplasms
5
Pancreatic Neoplasms
3
Cystadenocarcinoma, Serous
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Prostatic Neoplasms
2
Ovarian Diseases
2
Neoplasm Metastasis
2
Gonadal Disorders
2
Genital Neoplasms, Female
2
Genital Diseases, Female
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Carcinoma
2
Adnexal Diseases
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytopenia
1
Sarcoma
1
Recurrent/ Advanced Stage Endometrial Cancer Patients
1
Recurrence
1
Prostatic Diseases
1
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1
Platinum-resistant Ovarian Cancer
1
Interventions
pembrolizumab
19
Paclitaxel
10
Carboplatin
10
Magnetic Resonance Spectroscopy
9
Docetaxel
9
Cyclophosphamide
9
Specimen Handling
8
Cisplatin
8
Gemcitabine
7
Drug Therapy
7
sargramostim
6
Pemetrexed
6
Nivolumab
6
fludarabine
5
aldesleukin
5
Trastuzumab
5
Bevacizumab
5
Taxes
4
Fluorouracil
4
Blood Specimen Collection
4
Amifostine
4
veliparib
3
pegfilgrastim
3
Topotecan
3
Irinotecan
3
IFL protocol
3
Fluorodeoxyglucose F18
3
Etoposide
3
Early Intervention, Educational
3
tariquidar
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
niraparib
×
Gynecologic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts